Article info

Download PDFPDF

Extended report
Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)

Authors

  1. Correspondence to Dr Yoshikazu Nakaoka, Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute, Osaka 565-8565, Japan; ynakaoka{at}ncvc.go.jp
View Full Text

Citation

Nakaoka Y, Isobe M, Takei S, et al
Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)

Publication history

  • Received June 1, 2017
  • Revised October 25, 2017
  • Accepted October 31, 2017
  • First published November 30, 2017.
Online issue publication 
April 19, 2018

Article Versions